Tesamorelin: What the Research Shows About the GHRH-Analog Peptide

Tesamorelin is a synthetic peptide widely studied as a growth-hormone-releasing hormone (GHRH) analog. This guide summarizes what the published scientific literature has examined about tesamorelin, its molecular profile, and how it is handled in a research setting. It is written for researchers and is not medical guidance.

What is tesamorelin?

Tesamorelin (CAS 218949-48-5; molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S; molar mass ≈ 5136 g/mol) is a synthetic analog of human growth-hormone-releasing factor (GRF / GHRH). In research models it is studied for its ability to stimulate the synthesis and release of endogenous growth hormone. The active compound has been approved by regulators as a prescription medicine for a specific clinical indication, but the material supplied here is intended strictly for laboratory research and is not for human use.

Research-use note: Tesamorelin is supplied strictly for laboratory research. It is not a supplement and not for human or animal consumption. Nothing below describes or endorses human use.

How tesamorelin works (the mechanism studied)

Tesamorelin is characterized in the literature as a GHRH analog: it binds the GHRH receptor and, in study models, stimulates the pulsatile release of growth hormone from the pituitary, which in turn influences insulin-like growth factor 1 (IGF-1). Researchers have examined this GHRH–GH–IGF-1 axis as the compound’s primary mechanism of interest.

What researchers have studied

The published record on tesamorelin consists largely of clinical-trial data in the context of HIV-associated visceral fat accumulation. The most-cited studies include:

• Body-composition research — Falutz et al. (J Clin Endocrinol Metab, 2010) examined effects of tesamorelin on abdominal fat accumulation in a randomized placebo-controlled trial with a safety extension.
• Reviews — multiple peer-reviewed reviews have consolidated the GHRH-analog literature (e.g. Drugs, 2012).

These findings belong to the published research record and do not represent approved or validated uses of the research compound sold here.

Handling and reconstitution in the laboratory

Tesamorelin is typically supplied as a lyophilized powder for research use. Standard laboratory practice is to reconstitute it with bacteriostatic water, swirl (not shake) until dissolved, and store the reconstituted solution refrigerated (2–8 °C). The lyophilized powder is generally stored frozen and protected from light. (General lab-handling notes, not usage instructions.)

For research use only

All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. No statement here should be interpreted as medical advice.

Explore tesamorelin and related research peptides

• Tesamorelin 10mg — verified CAS, formula, and specifications
• CJC-1295 + Ipamorelin — related growth-hormone-axis research peptides
• Bacteriostatic Water 30ml — reconstitution diluent

References

1. Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Clin Endocrinol Metab. 2010. PubMed
2. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Review. 2012. PubMed
3. Tesamorelin (overview). StatPearls. PubMed